UNITED THERAPEUTICS Corp
UTHR Nasdaq
SEC CIK 1082554
Follow United Therapeutics
Weekly email: filings, results
Revenue, last quarter
$832.5M
+4.1% vs same quarter last year
Net income
$258.6M
−23.6% vs same quarter last year
EPS, diluted
$5.71
−20.3% vs same quarter last year
Operating cash flow
$306.5M
−45.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $3.2B | $1.3B |
| FY24 | $2.9B | $1.2B |
| FY23 | $2.3B | $984.8M |
| FY22 | $1.9B | $727.3M |
| FY21 | $1.7B | $475.8M |
| FY20 | $1.5B | $514.8M |
| FY19 | $1.4B | −$104.5M |
| FY18 | $1.6B | $589.2M |
| FY17 | $1.7B | $417.9M |
| FY16 | $1.6B | $713.7M |
| FY15 | $1.5B | $651.6M |
| FY14 | $1.3B | $340.1M |
| FY13 | $1.1B | $174.6M |
| FY12 | $916.1M | $304.4M |
| FY11 | $743.2M | $217.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 87.9% | 46.9% | 41.9% |
| FY24 | 89.2% | 47.9% | 41.5% |
| FY23 | 88.9% | 50.9% | 42.3% |
| FY22 | 92.2% | 50.6% | 37.6% |
| FY21 | 92.7% | 33% | 28.2% |
| FY20 | 92.7% | 40% | 34.7% |
| FY19 | 91.9% | −12.9% | −7.2% |
| FY18 | 87.8% | 49.5% | 36.2% |
| FY17 | 93.9% | 47.2% | 24.2% |
| FY16 | 95.5% | 66.4% | 44.6% |
| FY15 | 95.3% | 47.7% | 44.5% |
| FY14 | 89.5% | 41.8% | 26.4% |
| FY13 | 87.4% | 26.2% | 15.6% |
| FY12 | 85.9% | 46% | 33.2% |
| FY11 | 87.8% | 42.8% | 29.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $1B |
| FY24 | $1.1B |
| FY23 | $747.6M |
| FY22 | $663.7M |
| FY21 | $477.4M |
| FY20 | $696.4M |
| FY19 | −$290.3M |
| FY18 | $594M |
| FY17 | $387.9M |
| FY16 | $605.6M |
| FY15 | $333M |
| FY14 | $307.9M |
| FY13 | $393.4M |
| FY12 | $211.7M |
| FY11 | $214.2M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $1B |
| FY24 | $1B |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | $250M |
| FY16 | $500M |
| FY15 | $394.5M |
| FY14 | $483.1M |
| FY13 | $42.4M |
| FY12 | $188M |
| FY11 | $212M |
- United Therapeutics
- Healthcare median
Show the numbers
| Year | United Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 41.9% | −30.6% |
| FY24 | 41.5% | −47% |
| FY23 | 42.3% | −58% |
| FY22 | 37.6% | −80.4% |
| FY21 | 28.2% | −71.9% |
| FY20 | 34.7% | −62.2% |
| FY19 | −7.2% | −46.3% |
| FY18 | 36.2% | −49.6% |
| FY17 | 24.2% | −45.9% |
| FY16 | 44.6% | −36% |
| FY15 | 44.5% | −38.4% |
| FY14 | 26.4% | −35.5% |
| FY13 | 15.6% | −37.1% |
| FY12 | 33.2% | −29.1% |
| FY11 | 29.3% | −27.9% |